• 1
    Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 316.
  • 2
    Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 2: 1726.
  • 3
    Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. HEPATOLOGY 2000; 32: 689692.
  • 4
    Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134140.
  • 5
    Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142149.
  • 6
    Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112117.
  • 7
    Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 7179.
  • 8
    Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842845.
  • 9
    Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. HEPATOLOGY 2003; 37: 917923.
  • 10
    Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450455.
  • 11
    Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui J, Fung C, Karim R, et al. NASH and insulin resistance: insulin secretion and specific association with the insulin resistance syndrome. HEPATOLOGY 2002; 35: 373379.
  • 12
    Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, Banner BF. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421429.
  • 13
    George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311318.
  • 14
    Chitturi S, Weltman M, Farrell GC, McDonald D, Kench J, Liddle C, Samarasinghe D, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. HEPATOLOGY 2002; 36: 142149.
  • 15
    Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, McCullough AJ. Hepatic iron and nonalcoholic fatty liver disease. HEPATOLOGY 1999; 30: 847850.
  • 16
    Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1999; 30: 13561362.
  • 17
    Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. HEPATOLOGY 1990; 12: 11061110.
  • 18
    Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 11171123.
  • 19
    Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le Gall JY, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 11551163.
  • 20
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia 1985; 28: 412419.
  • 21
    Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 24022410.
  • 22
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med 1998; 15: 539553.
  • 23
    National Diabetes Data Group. Classification and diagnosis of diabetes and other categories of glucose intolerance. Diabetes 1979; 28: 10391057.
  • 24
    Matsuda M, De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999; 22: 14621470.
  • 25
    Cederholm J, Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 1990; 10: 167175.
  • 26
    Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001; 24: 539548.
  • 27
    Oberkanins C, Moritz A, De Villier JNP, Kotze MJ, Kury F. A reverse-hybridization assay for the rapid and simultaneous detection of nine HFE gene mutations. Genet Test 2000; 4: 121123.
  • 28
    Brittenham GM, Farrell DE, Harris JW, Feldman ES, Danish EH, Muir WA, Tripp JH, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982; 307: 16711675.
  • 29
    Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101: 1519.
  • 30
    Adams PC. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis? Am J Gastroenterol 2001; 96: 567569.
    Direct Link:
  • 31
    Barosi G, Salvaneschi L, Grasso M, Martinetti M, Marchetti M, Bodini U, Reggiani A, et al. High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy. Haematologica 2002; 87: 472478.
  • 32
    Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK.. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002; 122: 646651.
  • 33
    Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 24482455.
    Direct Link:
  • 34
    Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc'h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 2001; 116: 263270.
  • 35
    Piperno A, Trombini P, Gelosa M, Mauri V, Pecci V, Vergani A, Salvioni A, et al. Increased serum ferritin is common in men with essential hypertension. J Hypertens 2002; 20: 15131518.
  • 36
    Fernandez-Real JM, Ricart-Engel W, Arroyo E, Balanca R, Casamitjana-Abella R, Cabrero D, Fernandez-Castaner M, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998; 21: 6268.
  • 37
    Davis RJ, Corvera S, Czech MP. Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J Biol Chem 1986; 261: 87088711.
  • 38
    Sibille JC, Kondo H, Aisen P. Interactions between isolated hepatocytes and Kupffer cells in iron metabolism: a possible role for ferritin as an iron carrier protein. Hepatology 1988; 8: 296301.
  • 39
    Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, Conti M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. HEPATOLOGY 2001; 34: 738744.
  • 40
    Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jaross W, Hanefeld M. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002; 51: 743749.
  • 41
    Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 16731677.